Market Overview

UPDATE: Credit Suisse Initiates Sequenom at Underperform on Competitive Challenges

Related SQNM
Wedbush Securities Expects In-Line Results For Sequenom
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Credit Suisse initiated coverage on Sequenom (NASDAQ: SQNM) with an Underperform rating and a $4 price target.

Credit Suisse noted, "While we are excited about the scientific advance and volume potential that noninvasive prenatal genetic tests, including Sequenom's MaterniT21 PLUS, offer, we are concerned that the aggressive competitive dynamics we are already seeing (most notably with pricing) will limit the commercial potential of the test and cause the stock to underperform the rest of our coverage universe over the next 12 months."

Sequenom closed at $3.70 on Monday.

Latest Ratings for SQNM

Jun 2014William BlairUpgradesMarket PerformOutperform
Jan 2014Piper JaffrayDowngradesOverweightNeutral
Nov 2013Maxim GroupReiteratesBuy

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (SQNM)

Around the Web, We're Loving...